The bio and medical device company NanoEntek reported on the 11th that it achieved a turnaround in operating profit and net profit last year while expanding its performance in the U.S. men's health diagnostic market.
NanoEntek recorded consolidated sales of 30.5 billion won last year, a 13.5% increase compared to the previous year. Operating profit and net profit were 600 million won and 3.6 billion won, respectively, achieving a profit turnaround.
According to the company, NanoEntek is supplying male hormone diagnostic products and prostate diagnostic products to the 'Game Day' chain of men's specialty clinics across the U.S. So far, related equipment has been installed in more than 250 Game Day chain clinics.
A representative of NanoEntek noted, "Revenue growth through collaboration with Game Day in the U.S. and the global expansion strategy of the cell and gene therapy (CGT) platform is the driving force behind performance improvement," adding that the product for sex hormone-binding globulin (SHBG), which is currently undergoing U.S. Food and Drug Administration (FDA) approval, is also expected to be a significant additional growth driver in the male health diagnostic field.